A user shared progress pictures showing hairline improvement after 2 years of using topical Minoxidil, 1mg oral Finasteride, and sporadic microneedling. Another user praised the progress and shared mutual encouragement.
The conversation discusses the use of topical minoxidil and finasteride for hair loss, with some users combining them with oral treatments. Users share their experiences and opinions on effectiveness, cost, and convenience, with mixed views on whether topical or oral applications are superior.
The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.
The conversation is about the effectiveness of 0.25% topical finasteride compared to other concentrations and forms. Users discuss its potential for better scalp DHT reduction and fewer side effects, with some preferring topical over oral treatments.
The user "Specialist_Let_9455" shared their positive results after 6 months of using finasteride for hair loss. They plan to continue using finasteride for one year before considering other treatments.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
The user is experiencing significant hair shedding despite 2 years on finasteride, 1.5 years on RU58841, and 10 months on oral minoxidil, and is frustrated with the ongoing issue. Another user shares a similar experience of losing a lot of hair daily for the last 3 years.
User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.
Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.
Hair loss prevention and regrowth regimen includes finasteride, oral minoxidil, stemoxydine, hair growth serum, derma rolling, and ketocanazole shampoo. Users discuss efficacy, safety, and personal experiences with treatments.
The conversation discusses using topical minoxidil and finasteride, along with dermarolling and biotin shampoo, for hair loss treatment. It also explores supplements like NutraPro's hair growth formula and other products like tretinoin, Ducray shampoo, and Nizoral to enhance results.
User experiencing hair loss tried Minoxidil, Finasteride, Microneedling, Ketoconazole shampoo, and Biotin. Others suggest continuing current treatment for 1-2 years before considering Dutasteride and RU58841.
Naepo's 5-month progress report detailing their journey of treating male pattern baldness with dutasteride and oral minoxidil, which has already resulted in an encouraging improvement in hair density. Others have responded with appreciation for the thorough report and asked further questions about Naepo's educational background.
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
Significant hair regrowth was achieved in two months using oral finasteride, topical minoxidil, microneedling, and Nizoral shampoo. Some users mentioned side effects of finasteride, like low libido and pain, and recommended consulting a doctor or trying topical alternatives.
The user continues to experience hair loss despite using dutasteride 2.5mg, minoxidil 5mg, and ciclopirox shampoo, and plans to reassess after one year. Others report similar issues with dutasteride, with some switching to finasteride or adding RU58841.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
Treatments for hair loss, including the effectiveness and safety of Pyrilutamide compared to RU58841; experiences using both medications with varying results; and recommendations to try Pyrilutamide instead of RU58841.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.
A user has been taking Finasteride for hair loss for 10 months with no results and is considering whether it's due to seasonal shedding or the medication not working. Other users suggest that the dosage might be too low, that some people don't respond to Finasteride, and recommend trying Minoxidil or Dutasteride.
Microneedling with minoxidil significantly boosts hair growth, even for non-responders to minoxidil alone. The routine includes a 1.5mm dermaroller weekly and minoxidil twice daily, with some users adding finasteride and tretinoin.
A 41-year-old man experienced significant hair regrowth using topical finasteride (0.025%), minoxidil, microneedling every two weeks, and occasional Nizoral 2% shampoo. He advises against using creatine due to personal experience with increased hair shedding.
The user experienced significant hair regrowth after using Finasteride for 2 months and Minoxidil for 4 months, along with a derma roller. They reported no side effects from the treatments and noted that Finasteride seemed to contribute most to the progress.
A user experienced shedding after 7 months on Fin/Min spray despite good results and no change in treatment. Other users noted similar experiences and mentioned that shedding periods can be normal.
Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.